Among patients with diabetes inadequately controlled by metformin, SGLT2 inhibition reduced circulating biomarkers of inflammation and fibrosis compared to treatment with the insulin secretagogue glimepiride in 1–2 years follow up. Here, INS is linked to diabetes mellitus.